Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
UNC5293, a potent, orally available and highly MERTK-selective inhibitor.
Journal: European journal of medicinal chemistry
Published: March 04, 2021
A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
Journal: Leukemia research
Published: May 12, 2020
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Journal: Molecular cancer therapeutics
Published: May 03, 2018
The Current State of FLT3 Inhibition in Acute Myeloid Leukemia - Pitfalls and Promises.
Journal: Journal of cell signaling
Published: January 01, 2017
The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
Journal: Journal of thrombosis and haemostasis : JTH
Published: June 25, 2016
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
Journal: Journal of medicinal chemistry
Published: July 29, 2014
t(17;19) in Children with Acute Lymphocytic Leukemia: A Report of 3 Cases and a Review of the Literature.
Journal: Case reports in hematology
Published: November 19, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026